Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

DMP-695: ACS debut for new, orally active CRF1 antagonist

Sep. 7, 1998

Potent, orally active, second-generation neuroimmunophilin from Guilford

Sep. 7, 1998

Maruishi licenses rights to Chirocaine in Japan

Sep. 7, 1998

Potent mixed delta/mu-opioid agonist identified by Glaxo Wellcome/Delta team

Sep. 4, 1998

Taisho discovers potent and selective CRF1 receptor antagonists with anxiolytic effects

Sep. 4, 1998

P&U, U of Maryland describe inhibitors of kynurenine aminotransferase

Sep. 4, 1998

Neuroprotective and antioxidant phenazines designed at Nippon Chemiphar

Sep. 4, 1998

Regeneron receives milestone payment from Sumitomo related to BDNF development

Sep. 4, 1998

Pfizer/Neurogen anxiolytic advances in clinical trials

Sep. 3, 1998

Pharmacological profile of new acetylcholinesterase inhibitor: T-82

Sep. 3, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Regulatory actions for July 27, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma,...